|
| 37812652 | Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma. | Clin Cancer Res | 2024 |
| 37990009 | Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer. | Nat Commun | 2023 |
| 37915590 | Comprehensive characterization of patient-derived xenograft models of pediatric leukemia. | iScience | 2023 |
| 35312779 | Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. | Mol Cancer Ther | 2022 |
| 35797217 | Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models. | Clin Cancer Res | 2022 |
| 35450020 | Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma. | Cancer Drug Resist | 2022 |
| 35657346 | Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium. | Mol Cancer Ther | 2022 |
| 36242092 | PARP1-MGMT complex underpins pathway crosstalk in O<sup>6</sup>-methylguanine repair. | J Hematol Oncol | 2022 |
| 35129140 | Extrarenal Anaplastic Wilms Tumor: A Case Report With Genomic Analysis and Tumor Models. | J Pediatr Hematol Oncol | 2022 |
| 32810235 | PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models. | Nucleic Acids Res | 2021 |
| 33619171 | The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. | Clin Cancer Res | 2021 |
| 33916592 | Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing. | J Clin Med | 2021 |
| 33916177 | Recent Developments in Nanomedicine for Pediatric Cancer. | J Clin Med | 2021 |
| 35098099 | PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma. | iScience | 2021 |
| 34453478 | In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). | Pediatr Blood Cancer | 2021 |
| 33089597 | In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium. | Pediatr Blood Cancer | 2021 |
| 33323380 | A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. | Cancer Res | 2021 |
| 32207565 | Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. | Pediatr Blood Cancer | 2020 |
| 31927611 | Prospective use of the single-mouse experimental design for the evaluation of PLX038A. | Cancer Chemother Pharmacol | 2020 |
| 31975571 | Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. | Pediatr Blood Cancer | 2020 |
| 32706456 | Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. | Pediatr Blood Cancer | 2020 |
| 32184294 | Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts. | Clin Cancer Res | 2020 |
| 32333633 | Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium. | Pediatr Blood Cancer | 2020 |
| 30563935 | Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. | Clin Cancer Res | 2019 |
| 31693904 | Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. | Cell Rep | 2019 |
| 31921673 | Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma. | Front Oncol | 2019 |
| 31558580 | Challenges and Opportunities for Childhood Cancer Drug Development. | Pharmacol Rev | 2019 |
| 31099166 | Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. | Pediatr Blood Cancer | 2019 |
| 31012549 | Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts. | Pediatr Blood Cancer | 2019 |
| 28921800 | Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2018 |
| 29080385 | Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. | Pediatr Blood Cancer | 2018 |
| 27555605 | Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2017 |
| 28119366 | Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL. | Clin Cancer Res | 2017 |
| 27786412 | Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2017 |
| 27650817 | Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2017 |
| 26797892 | Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2016 |
| 26398108 | Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. | Pediatr Blood Cancer | 2016 |
| 27302164 | Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. | Cancer Res | 2016 |
| 27238606 | Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2016 |
| 27496711 | Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. | Cancer Res | 2016 |
| 27193096 | Identifying novel therapeutic agents using xenograft models of pediatric cancer. | Cancer Chemother Pharmacol | 2016 |
| 27343252 | Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. | Blood | 2016 |
| 26960974 | Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia. | Cancer Res | 2016 |
| 25263539 | Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. | Pediatr Blood Cancer | 2015 |
| 26380223 | Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. | Front Oncol | 2015 |
| 26154614 | Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2015 |
| 26116659 | AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. | Blood | 2015 |
| 25832557 | Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. | Pediatr Blood Cancer | 2015 |
| 25981859 | Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. | Pediatr Blood Cancer | 2015 |
| 25809532 | Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP). | Pediatr Blood Cancer | 2015 |